CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 473 enrolled
Drug / intervention
Delgocitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04872101
NCT04872101Phase 3Completed
CompareCT.gov

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)

LEO Pharma·interventional·Posted May 4, 2021·Updated Apr 8, 2025

In Brief

A Phase 3 clinical trial evaluating Delgocitinib cream and Cream vehicle for Chronic Hand Eczema. Completed, enrolled 473 participants across 50 sites in 7 countries.

Detailed Summary

This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hand Eczema
CountriesBelgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 4, 2021
Enrollment StartMay 25, 2021
Primary CompletionDec 27, 2022
Study CompletionJan 6, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.2 years ago

Interventions

Delgocitinib creamdrug

Cream for topical application

Cream vehicledrug

The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.